{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:34:35Z","timestamp":1781624075449,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP19K17153"],"award-info":[{"award-number":["JP19K17153"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Radiotherapy (RT) destroys cancer cells and activates the immune system while suppressing the immunity of tumor-associated tissues, including the tumor microenvironment (TME). However, to date, no anti-tumor therapeutic strategy that uses these immune mechanisms has been established. This study investigated changes in the immunity of the TME during standard radical RT for cervical cancer combined with external beam RT and brachytherapy and determined whether these changes affect prognosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Twenty-six patients who had completed radical RT for cervical cancer were categorized into the following two groups according to whether the cancer recurred and\/or metastasized within 2\u00a0years after the start of treatment: treatment failure (n\u2009=\u200914) and treatment success (n\u2009=\u200912). We assessed the expression of programmed death 1, programmed death ligand 1 (PD-L1), cluster of\u00a0differentiation (CD) 8, CD68, CD163, Forkhead box protein P3, and hypoxia-inducible factor-1\u03b1 in the TME of cervical tissues collected periodically during treatment and evaluated the difference in expression rates of each marker between the success and failure groups and assessed its effect on prognosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The expression levels of PD-L1 and CD163 in the TME in the treatment success group were lower than those in the treatment failure group at the midpoint during brachytherapy (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01 and <jats:italic>p<\/jats:italic>\u2009=\u20090.08, respectively), and the 2-year progression-free-survival (PFS) rate depended on the expression levels of PD-L1 and CD163 (<jats:italic>p<\/jats:italic>\u2009=\u20090.04 and <jats:italic>p<\/jats:italic>\u2009=\u20090.02, respectively).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The expression rates of CD163 and PD-L1 in the TME during brachytherapy were related to treatment response and the 2-year PFS. This study may increase our understanding of tumor-associated immunity in the TME and aid in the development of therapies targeting PD-L1 or M2 macrophages in the TME in conjunction with RT, especially brachytherapy, for cervical cancer patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-023-02230-7","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T12:02:45Z","timestamp":1677153765000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dynamics in the expression of programmed death ligand 1 and cluster of differentiation 163 in the tumor microenvironment of uterine cervical cancer: a single-center retrospective study"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8610-6049","authenticated-orcid":false,"given":"Yusaku","family":"Miyata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4909-0217","authenticated-orcid":false,"given":"Etsuyo","family":"Ogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1173-5347","authenticated-orcid":false,"given":"Toshi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2349-7200","authenticated-orcid":false,"given":"Hideki","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6761-167X","authenticated-orcid":false,"given":"Naotake","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6087-8873","authenticated-orcid":false,"given":"Kimio","family":"Ushijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4081-2519","authenticated-orcid":false,"given":"Akihiko","family":"Kawahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2657-8604","authenticated-orcid":false,"given":"Jun","family":"Akiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0508-8641","authenticated-orcid":false,"given":"Hitoshi","family":"Obara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3713-3099","authenticated-orcid":false,"given":"Tatsuyuki","family":"Kakuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"2230_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1159\/000448902","volume":"39","author":"D Vordermark","year":"2016","unstructured":"Vordermark D. Radiotherapy of cervical cancer. Oncol Res Treat. 2016;39:516\u201320. https:\/\/doi.org\/10.1159\/000448902.","journal-title":"Oncol Res Treat"},{"key":"2230_CR2","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nature18294","volume":"534","author":"K Kataoka","year":"2016","unstructured":"Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, et al. Aberrant PD-L1 expression through 3\u2019-UTR disruption in multiple cancers. Nature. 2016;534:402\u20136. https:\/\/doi.org\/10.1038\/nature18294.","journal-title":"Nature"},{"key":"2230_CR3","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1084\/jem.20090847","volume":"206","author":"LM Francisco","year":"2009","unstructured":"Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206:3015\u201329. https:\/\/doi.org\/10.1084\/jem.20090847.","journal-title":"J Exp Med"},{"key":"2230_CR4","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99:12293\u20137. https:\/\/doi.org\/10.1073\/pnas.192461099.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2230_CR5","doi-asserted-by":"publisher","first-page":"5538","DOI":"10.4049\/jimmunol.169.10.5538","volume":"169","author":"T Yamazaki","year":"2002","unstructured":"Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol. 2002;169:5538\u201345. https:\/\/doi.org\/10.4049\/jimmunol.169.10.5538.","journal-title":"J Immunol"},{"key":"2230_CR6","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14:847\u201356. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0983.","journal-title":"Mol Cancer Ther"},{"key":"2230_CR7","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.18.01265","volume":"37","author":"HC Chung","year":"2019","unstructured":"Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2019;37:1470\u20138. https:\/\/doi.org\/10.1200\/JCO.18.01265.","journal-title":"J Clin Oncol"},{"key":"2230_CR8","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.19.00739","volume":"37","author":"RW Naumann","year":"2019","unstructured":"Naumann RW, Hollebecque A, Meyer T, Devlin MJ, Oaknin A, Kerger J, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I\/II checkmate 358 trial. J Clin Oncol. 2019;37:2825\u201334. https:\/\/doi.org\/10.1200\/JCO.19.00739.","journal-title":"J Clin Oncol"},{"key":"2230_CR9","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.3390\/ijms20133212","volume":"20","author":"M Jarosz-Biej","year":"2019","unstructured":"Jarosz-Biej M, Smolarczyk R, Cichon T, Kulach N. Tumor microenvironment as a \u201cgame changer\u201d in cancer radiotherapy. Int J Mol Sci. 2019;20:3212. https:\/\/doi.org\/10.3390\/ijms20133212.","journal-title":"Int J Mol Sci"},{"key":"2230_CR10","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","volume":"8","author":"H Sato","year":"2017","unstructured":"Sato H, Niimi A, Yasuhara T, Permata TBM, Hagiwara Y, Isono M, et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun. 2017;8:1751. https:\/\/doi.org\/10.1038\/s41467-017-01883-9.","journal-title":"Nat Commun"},{"key":"2230_CR11","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1136\/ijgc-00009577-200303000-00012","volume":"13","author":"K Ohara","year":"2003","unstructured":"Ohara K, Tsunoda H, Nishida M, Sugahara S, Hashimoto T, Shioyama Y, et al. Use of small pelvic field instead of whole pelvic field in postoperative radiotherapy for node-negative, high-risk stages I and II cervical squamous cell carcinoma. Int J Gynecol Cancer. 2003;13:170\u20136. https:\/\/doi.org\/10.1136\/ijgc-00009577-200303000-00012.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"2230_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1136\/10.1016\/j.ijgo.2009.02.009","volume":"105","author":"S Pecorelli","year":"2009","unstructured":"Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet. 2009;105(2):107\u20138. https:\/\/doi.org\/10.1136\/10.1016\/j.ijgo.2009.02.009.","journal-title":"Int J Gynaecol Obstet"},{"key":"2230_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"2230_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16:275\u201387. https:\/\/doi.org\/10.1038\/nrc.2016.36.","journal-title":"Nat Rev Cancer"},{"key":"2230_CR15","doi-asserted-by":"publisher","first-page":"583084","DOI":"10.3389\/fimmu.2020.583084","volume":"11","author":"Y Pan","year":"2020","unstructured":"Pan Y, Yu Y, Wang X, Zhang T. Tumor-associated macrophages in tumor immunity. Front Immunol. 2020;11:583084. https:\/\/doi.org\/10.3389\/fimmu.2020.583084.","journal-title":"Front Immunol"},{"key":"2230_CR16","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ni904","volume":"4","author":"JD Fontenot","year":"2003","unstructured":"Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4(+)CD25(+) regulatory T cells. Nat Immunol. 2003;4:330\u20136. https:\/\/doi.org\/10.1038\/ni904.","journal-title":"Nat Immunol"},{"key":"2230_CR17","doi-asserted-by":"publisher","first-page":"6842963","DOI":"10.1155\/2020\/6842963","volume":"2020","author":"Y Liu","year":"2020","unstructured":"Liu Y, Li L, Li Y, Zhao X. Research progress on tumor-associated macrophages and inflammation in cervical cancer. Biomed Res Int. 2020;2020:6842963. https:\/\/doi.org\/10.1155\/2020\/6842963.","journal-title":"Biomed Res Int"},{"key":"2230_CR18","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.3389\/fimmu.2019.01643","volume":"10","author":"Z Zong","year":"2019","unstructured":"Zong Z, Zou J, Mao R, Ma C, Li N, Wang J, et al. M1 macrophages induce PD-L1 expression in hepatocellular carcinoma cells through IL-1beta signaling. Front Immunol. 2019;10:1643. https:\/\/doi.org\/10.3389\/fimmu.2019.01643.","journal-title":"Front Immunol"},{"key":"2230_CR19","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1158\/0008-5472.CAN-12-4354","volume":"73","author":"Y Huang","year":"2013","unstructured":"Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 2013;73:2943\u20138. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-4354.","journal-title":"Cancer Res"},{"key":"2230_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1667\/RR1013.1","volume":"169","author":"F Tago","year":"2008","unstructured":"Tago F, Tsukimoto M, Nakatsukasa H, Kojima S. Repeated 0.5-Gy gamma irradiation attenuates autoimmune disease in MRL-lpr\/lpr mice with suppression of CD3+CD4-CD8-B220+ T-cell proliferation and with up-regulation of CD4+CD25+Foxp3+ regulatory T cells. Radiat Res. 2008;169:59\u201366. https:\/\/doi.org\/10.1667\/RR1013.1.","journal-title":"Radiat Res"},{"key":"2230_CR21","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1011\/gad.1881410","volume":"24","author":"N Takeda","year":"2010","unstructured":"Takeda N, O\u2019Dea EL, Doedens A, Kim JW, Weidemann A, Stockmann C, et al. Differential activation and antagonistic function of HIF-\u03b1 isoforms in macrophages are essential for NO homeostasis. Genes Dev. 2010;24:491\u2013501. https:\/\/doi.org\/10.1011\/gad.1881410.","journal-title":"Genes Dev"},{"key":"2230_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.brachy.2019.09.009","volume":"19","author":"MA Berenguer Frances","year":"2020","unstructured":"Berenguer Frances MA, Linares-Galiana I, Canas Cortes R, Marin IBS, Gutierrez Miguelez C, Najjari D, et al. Changes of CD68, CD163, and PD-L1 tumor expression during high-dose-rate and pulsed-dose-rate brachytherapy for cervical cancer. Brachytherapy. 2020;19:51\u20139. https:\/\/doi.org\/10.1016\/j.brachy.2019.09.009.","journal-title":"Brachytherapy"},{"key":"2230_CR23","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","volume":"37","author":"V Kumar","year":"2016","unstructured":"Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37:208\u201320. https:\/\/doi.org\/10.1016\/j.it.2016.01.004.","journal-title":"Trends Immunol"},{"key":"2230_CR24","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.yexcr.2017.08.028","volume":"359","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Du W, Chen Z, Xiang C. Upregulation of PD-L1 by SPP1 mediates macrophage polarization and facilitates immune escape in lung adenocarcinoma. Exp Cell Res. 2017;359:449\u201357. https:\/\/doi.org\/10.1016\/j.yexcr.2017.08.028.","journal-title":"Exp Cell Res"},{"key":"2230_CR25","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00066-019-01571-1","volume":"196","author":"T Tsuchiya","year":"2020","unstructured":"Tsuchiya T, Someya M, Takada Y, Hasegawa T, Kitagawa M, Fukushima Y, et al. Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy. Strahlenther Onkol. 2020;196:725\u201335. https:\/\/doi.org\/10.1007\/s00066-019-01571-1.","journal-title":"Strahlenther Onkol"},{"key":"2230_CR26","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00795-021-00290-w","volume":"54","author":"M Someya","year":"2021","unstructured":"Someya M, Tsuchiya T, Fukushima Y, Hasegawa T, Hori M, Kitagawa M, et al. Prediction of treatment response from the microenvironment of tumor immunity in cervical cancer patients treated with chemoradiotherapy. Med Mol Morphol. 2021;54:245\u201352. https:\/\/doi.org\/10.1007\/s00795-021-00290-w.","journal-title":"Med Mol Morphol"},{"key":"2230_CR27","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/imm.12380","volume":"143","author":"V Kumar","year":"2014","unstructured":"Kumar V, Gabrilovich DI. Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. Immunology. 2014;143:512\u20139. https:\/\/doi.org\/10.1111\/imm.12380.","journal-title":"Immunology"},{"key":"2230_CR28","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et al. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211:781\u201390. https:\/\/doi.org\/10.1084\/jem.20131916.","journal-title":"J Exp Med"},{"key":"2230_CR29","unstructured":"Hall EJ, Giaccia AJ. Radiobiology for the radiologist. In: Wolters K, editor. Lippincott Williams & Wilkins (LWW); 2019. p. 82\u20133."},{"key":"2230_CR30","doi-asserted-by":"publisher","first-page":"e0017122","DOI":"10.1128\/mcb.00171-22","volume":"42","author":"A Onorati","year":"2022","unstructured":"Onorati A, Havas AP, Lin B, Rajagopal J, Sen P, Adams PD, et al. Upregulation of PD-L1 in senescence and aging. Mol Cell Biol. 2022;42:e0017122. https:\/\/doi.org\/10.1128\/mcb.00171-22.","journal-title":"Mol Cell Biol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02230-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-023-02230-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02230-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T12:03:24Z","timestamp":1677153804000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-023-02230-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2230"],"URL":"https:\/\/doi.org\/10.1186\/s13014-023-02230-7","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,23]]},"assertion":[{"value":"7 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We obtained approval from the ethics committee of our institution to use these cervical tissue samples for this study (No. 19191).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}